8th Cell and Gene Therapy Analytical Development Summit

When:
Tuesday, Dec 01, 2026 8:00a -
Thursday, Dec 03, 2026 5:00p

Where:
Revere Hotel Boston Common
200 Stuart Street
Boston, Massachusetts 02116

EventScheduled OfflineEventAttendanceMode

Admission:
$2299.00 - $5297.00

Hosted by:
...
evvnt.com Account #11193

Categories:
Lectures & Conferences

Event website:
https://go.evvnt.com/3790208-0?pid=5248

Optimizing Characterization, Delivery Efficiency, and Potency Assay Validation to Demonstrate Product Safety, Quality and Efficacy of Cell and Gene Therapies to Drive Clinical and Commercial Approval

Landmark approvals from Orca Bio, Rocket Pharmaceuticals, and Regeneron, growing momentum behind in vivo CAR-T and autoimmune cell therapies, and new FDA initiatives designed to accelerate individualized genetic medicines are opening exciting opportunities across the industry. Yet these advances are also raising the bar for how therapies are characterized, controlled, and approved.


As novel therapies become more complex and development timelines tighten, analytical development is moving to the center of decision-making. From establishing meaningful potency assays and demonstrating comparability to defining biomarkers and generating robust product characterization data, analytical strategies are increasingly shaping whether programs progress successfully.


The 8th Cell and Gene Therapy Analytical Development Summit is the industry's leading forum dedicated exclusively to analytical development across cell and gene therapy. Bringing together analytical development, QC, characterization, CMC, and regulatory leaders, this is where the community comes together to share practical solutions, benchmark approaches, and stay ahead of evolving scientific developments and regulatory expectations.


For organizations looking to accelerate development, validate their strategies, and uncover proven approaches they can apply immediately, this is the meeting to attend in 2026.


URLs:

Tickets: https://go.evvnt.com/3790208-2?pid=5248

Brochure: https://go.evvnt.com/3790208-3?pid=5248


Prices:

Drug Developer Pricing - Conference + 2 Workshops: USD 3597.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 3148.00,

Drug Developer Pricing - Conference Only: USD 2699.00,

Academic Pricing - Conference + 2 Workshops: USD 2997.00,

Academic Pricing - Conference + 1 Workshop: USD 2648.00,

Academic Pricing - Conference Only: USD 2299.00,

Service Provider Pricing - Conference + 2 Workshops: USD 5297.00,

Service Provider Pricing - Conference + 1 Workshop: USD 4548.00,

Service Provider Pricing - Conference Only: USD 3799.00


Speakers: Jing Li Director, Clinical Pharmacology and Pharmacometrics, Alexion Pharmaceutic als, Amy Hsu, Principal Research Associate, Analytical Development, Astellas Gene Therapies, Jennifer Fox, Director, Analytical Sciences and Technology, AstraZeneca, Akshata Ijantkar, Senior Principal Scientist, Bristol Myers Squibb, Mateusz Dobrowolski, Scientist, Johnson and Johnson, Kevin Johnson, Director, Analytical Operations, Flow Cytometry Analytical Development, Kite Pharma Inc, Connie Tsai, Director, Cell and Gene Therapy Analytical Development, Novartis AG, Swarup Dey, Principal Scientist, Regeneron Pharmaceuticals, Sviatlana Rose, Principal Scientist, Sanofi, Lai Shi, Senior Scientist, Sanofi, Jiangli Yan, Senior Director, Analytical Science and Technology, Vertex Pharmaceuticals, Fan Yang, Vice President, Cell Therapy, Aisar Biotechnology, Jorge Santiago-Ortiz, Vice President, CMC and Regulatory Affairs, Apertura Gene Therapy, Xiaojin Liu, Scientist, Ascidian Therapeutics, Nam Tonthat, Senior Director, Analytical Sciences, Asklepios BioPharmaceutical, Inc. (AskBio), Andy Yang, Scientist I, Analytical and Quality Control, BlueRock Therapeutics, Michael White, CMC Lead, Celosia Therapeutics, Kelan Hlavaty, Senior Director, Technical Operations, eGenesis Bio, Ian Bayles, Analytical Assay Development Manager and Head of Quality Control, Expression Therapeutics LLC, Bryan Hancock, Principal Scientist, Product Characterization and Analytical Development, Fate Therapeutics, Alex Ng, Chief Scientific Officer and Co-Founder, GC Therapeutics, Scott Jeffers, Chief Technology Officer, GenSight Biologics, Angela Holton, Executive Director, IOVANCE Biotherapeutics, Inc., Kate Von, Alt Scientist, Exploratory Immuno-Oncology, KSQ Therapeutics, Caryn Cloer, Principal Scientist, ProKidney, Uditha deAlwis, Vice President, Analytical Development and Quality Control, Sarepta Therapeutics, Cristiano Vieira, Senior Scientist, Analytical Development, Solid Biosciences, Justin Rectenwald, Associate Director, Analytical Development, Taysha Gene Therapies, Inc., Benjamin Hall, Associate Director, Analytical Development, Tessera Therapeutics, Hima Ramachandrareddy, Senior Scientist II, Voyager Therapeutics Inc, Ruud Hulspas, Technical Director, Process Development, Dana-Farber Cancer Institute, Peter Lopez, Research Associate Professor of Pathology, NYU Grossman School of Medicine, Xikun Liu, Senior Analytical Development Manager, Stanford University

Share this event

Add to:

Reddit
12/01/2026 08:00:00 12/03/2026 17:00:00 America/New_York 8th Cell and Gene Therapy Analytical Development Summit <p>Optimizing Characterization, Delivery Efficiency, and Potency Assay Validation to Demonstrate Product Safety, Quality and Efficacy of Cell and Gene Therapies to Drive Clinical and Commercial App...

https://www.thebostoncalendar.com/events/8th-cell-and-gene-therapy-analytical-development-summit Revere Hotel Boston Common, Boston, Massachusetts 02116 false MM/DD/YYYY

Sponsored events